A Contemporary Analysis of Urethral Recurrence following Radical Cystectomy.


Journal

The Journal of urology
ISSN: 1527-3792
Titre abrégé: J Urol
Pays: United States
ID NLM: 0376374

Informations de publication

Date de publication:
10 2021
Historique:
pubmed: 26 5 2021
medline: 30 9 2021
entrez: 25 5 2021
Statut: ppublish

Résumé

Oncologic outcomes following urethral recurrence (UR) remain incompletely described, with reports limited by small cohort sizes. We evaluated risk factors for UR as well as cancer-specific survival (CSS) and overall survival (OS) among patients with UR. We reviewed our institutional radical cystectomy (RC) registry to identify patients with UR. Cox proportional hazards regression was used to assess risk factors for UR. Kaplan-Meier and Cox models were used to assess the relationship between UR and CSS/OS as well as to compare outcomes following symptomatic vs asymptomatic presentation of UR. Overall, 2,930 patients underwent RC from 1980 to 2018, with a median postoperative followup of 7.1 years (IQR 2.8-13.1), of whom 144 (4.9%) were subsequently diagnosed with UR. Carcinoma in situ (HR 1.98, 95% CI 1.30-3.04), multifocal disease (HR 1.59, 95% CI 1.07-2.36) and prostatic urethral involvement at RC (HR 3.01, 95% CI 1.98-4.57) were associated with increased risk of UR. UR was associated with decreased CSS (HR 7.30, 95% CI 5.46-9.76) and OS (HR 1.86, 95% CI 1.54-2.24). A total of 63/144 patients were diagnosed with UR based on symptoms, while 104/144 patients with UR underwent urethrectomy. Patients with symptomatic UR had higher tumor stage at urethrectomy (≥pT2 in 13.1% vs 3.1%, p=0.007), while patients with asymptomatic UR experienced longer median CSS (12.1 vs 6.1 years) and OS (8.30 vs 4.82 years; p=0.05 for both). We identified pathological risk factors for UR after RC and report adverse subsequent survival outcomes for these patients. Presentation with symptomatic UR was associated with higher tumor stage and poorer prognosis, supporting a value to continued urethral surveillance after RC.

Identifiants

pubmed: 34032500
doi: 10.1097/JU.0000000000001842
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

970-977

Commentaires et corrections

Type : CommentIn

Auteurs

Abhinav Khanna (A)

Department of Urology, Mayo Clinic, Rochester, Minnesota.

Andrew Zganjar (A)

Department of Urology, Mayo Clinic, Rochester, Minnesota.

Timothy Lyon (T)

Department of Urology, Mayo Clinic, Jacksonville, Florida.

Paras Shah (P)

Department of Urology, Mayo Clinic, Rochester, Minnesota.

Matthew K Tollefson (MK)

Department of Urology, Mayo Clinic, Rochester, Minnesota.

R Jeffrey Karnes (RJ)

Department of Urology, Mayo Clinic, Rochester, Minnesota.

Robert Tarrell (R)

Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.

Prabin Thapa (P)

Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.

R Houston Thompson (RH)

Department of Urology, Mayo Clinic, Rochester, Minnesota.

Igor Frank (I)

Department of Urology, Mayo Clinic, Rochester, Minnesota.

Stephen A Boorjian (SA)

Department of Urology, Mayo Clinic, Rochester, Minnesota.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH